Processing

Please wait...

Settings

Settings

Goto Application

1. WO2019139714 - PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS

Publication Number WO/2019/139714
Publication Date 18.07.2019
International Application No. PCT/US2018/065200
International Filing Date 12.12.2018
IPC
C07D 487/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61P 37/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
A61P 11/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
CPC
A61P 11/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
A61P 37/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 519/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
519Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applicants
  • GENENTECH, INC. [US]/[US] (US)
  • F. HOFFMANN-LA ROCHE AG [CH]/[CH] (AllExceptUS)
Inventors
  • ZAK, Mark
  • GIBBONS, Paul
  • CHENG, Yun-Xing
  • GOODACRE, Simon Charles
Agents
  • KALE, Tamara A.
  • ACKERMAN, Lily J.
  • AUSENHUS, Scott L.
  • BERENDT, Frank JN
  • BONE, Richard G.A.
  • BUCKWALTER, Brian L.
  • CHANG, Y. Elaine
  • CHI, I. Shannon
  • CLARK, Kevin M.
  • COBURN, Cara M.
  • COLANTONIO, Jessica R.
  • CRISSEY, Todd M.
  • CUI, Steven
  • DAVIS, Jennifer L.
  • DREGER, Ginger
  • DUFFIELD, Jonathan J.
  • GHOSE, Shameek
  • HALL, Robert C.
  • HEIDER, Julie A.
  • HILL, Laurie L.
  • JOHNSTON, Sean A.
  • KAFKA, Mark D.
  • KALINOWSKI, Grant E.
  • LEE, Wendy M.
  • LI, Qianru
  • MCCLELLAN, Kelly B.
  • RICHARDSON, Jessica L.
  • ROPP, Traci H.
  • SCOTT, Derek B.
  • SCHWARTZ, Timothy R.
  • SHERMAN, Daniel E.
  • SHOLTZ, Charles K.
  • TAN, Anna M.
  • TIAN, Zong-Qiang Bill
  • WAIS, Rebecca J.
Priority Data
PCT/CN2018/07256815.01.2018CN
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS
(FR) COMPOSÉS PYRAZOLOPYRIMIDINE UTILISÉS EN TANT QU'INHIBITEURS DE JAK
Abstract
(EN)
Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
(FR)
L'invention concerne des composés et des sels de ceux-ci qui sont utiles en tant qu'inhibiteurs de kinase JAK. L'invention concerne également des compositions pharmaceutiques comprenant un tel inhibiteur de JAK et un transporteur, adjuvant ou véhicule pharmaceutiquement acceptable, ainsi que des procédés permettant de traiter ou d'atténuer la gravité d'une maladie ou d'une affection sensible à l'inhibition d'une activité de Janus kinase chez un patient.
Latest bibliographic data on file with the International Bureau